Scoop: AbbVie terminates early-stage study of I-Mab's antibody, another clinical setback in CD47 field
The CD47 field faced setbacks earlier this year when Gilead’s magrolimab was hit with partial clinical holds, and another clinical hurdle can be added to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
